Evidence & Research Status
Researchers evaluating SS-31, MOTS-c, and NAD+ often assume these three mitochondrial-adjacent peptides and compounds are interchangeable "energy" or "longevity" tools. This mitochondrial peptide…
Evidence Level reflects the general state of published research for this compound category and is not a claim about the safety, efficacy, or approval status of any product sold on this site. All compounds are offered strictly for research use.
Researchers evaluating SS-31, MOTS-c, and NAD+ often assume these three mitochondrial-adjacent peptides and compounds are interchangeable “energy” or “longevity” tools. This mitochondrial peptide comparison lays out why they are not: each targets a different point in cellular energy metabolism, has a distinct evidence base, and carries a different regulatory status — differences that matter for how the research literature should be read and how each compound should be positioned.
Quick comparison
| SS-31 / Elamipretide | MOTS-c | NAD+ / NAD Precursors | |
|---|---|---|---|
| Primary target | Mitochondrial inner membrane / cardiolipin | Metabolic signaling, particularly AMPK | Cellular redox metabolism / coenzyme availability |
| Mechanism category | Mitochondrial membrane stabilization | Mitochondrial-to-nuclear metabolic signaling | Coenzyme for redox reactions and sirtuin/PARP activity |
| Human clinical evidence | Most developed of the three (multiple Phase 2/3 trials) | Very limited — largely preclinical | Substantial but inconsistent across trials |
| Regulatory status | FDA-approved as Forzinity for one narrow indication only | Investigational; not on any FDA bulk drug substance list | Available as dietary-supplement precursors (NMN, NR); not FDA-approved as a drug |
SS-31 (elamipretide): the mitochondrial membrane approach
SS-31 concentrates at the inner mitochondrial membrane and interacts with cardiolipin, a phospholipid central to electron-transport-chain organization. Researchers have studied it as: membrane stabilization → improved electron transport chain efficiency → reduced mitochondrial reactive oxygen species → downstream cellular effects. This makes it the most directly mitochondria-targeted of the three compounds discussed here.
On insulin sensitivity specifically, researchers consider the connection indirect: if impaired muscle mitochondrial function contributes to reduced metabolic flexibility, restoring mitochondrial efficiency could plausibly support downstream glucose handling — but this remains a mechanistic hypothesis rather than a demonstrated effect in human insulin-sensitivity studies.
Regulatory note: elamipretide received FDA accelerated approval as Forzinity (elamipretide HCl) on September 19, 2025, specifically to improve muscle strength in patients with Barth syndrome weighing at least 30 kg — the first mitochondria-targeted therapy to reach approval. That approval is narrow: it does not extend to longevity use, general mitochondrial support, insulin sensitivity, or any indication beyond Barth syndrome muscle strength, and continued approval is contingent on a confirmatory trial. Research-use SS-31 sold for laboratory study is a separate product from the approved drug and carries no approval of its own.
MOTS-c: the metabolic signaling messenger
MOTS-c is a peptide encoded within the mitochondrial genome whose research role centers on metabolic signaling — particularly AMPK activation, glucose utilization, and skeletal muscle metabolism. Researchers have proposed a pathway along the lines of: metabolic stress signal → AMPK activation → altered glucose utilization and metabolic flexibility, a distinct mechanism from SS-31’s structural membrane role.
Preclinical studies have reported improvements in insulin sensitivity, glucose tolerance, and markers of obesity-related metabolic dysfunction in animal models. Human evidence remains substantially thinner than the animal literature — this is a preclinical research story more than a clinical one at this stage.
Regulatory note: MOTS-c’s compounding status has moved twice in recent months and is worth stating precisely. FDA staff briefing materials published ahead of the July 23–24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting proposed that MOTS-c and six other peptides not be added to the 503A Bulks List, citing insufficient human exposure and safety data. At the meeting itself, however, the committee narrowly voted to recommend MOTS-c for 503A inclusion (7–5, two abstentions) — overriding FDA staff’s own recommendation, alongside similar votes for BPC-157, KPV, TB-500, Semax, and Epitalon. That committee recommendation is still non-binding: FDA has not added MOTS-c to the 503A Bulks List, and formal notice-and-comment rulemaking would be required before that changes. Researchers should treat MOTS-c’s compounding status as unsettled and under active regulatory review, not as settled in either direction.
NAD+ and NAD precursors: the fuel-transfer coenzyme
NAD+ is not a signaling peptide but a coenzyme required throughout cellular metabolism, cycling between NAD+ and NADH to support electron transport and ATP production, and interacting with sirtuins and PARPs in cellular stress-response pathways. That broad mechanistic role is part of why NAD+ biology is so closely tied to longevity research.
Human evidence for NAD-precursor supplementation (NMN, NR) on insulin sensitivity is genuinely mixed rather than uniformly positive. A randomized trial in overweight/obese postmenopausal women with prediabetes reported improved muscle insulin sensitivity and insulin signaling after NMN supplementation. Other trials — including NR supplementation in obese insulin-resistant men — found no significant improvement in insulin sensitivity, glucose disposal, or energy expenditure, and no significant change in skeletal-muscle mitochondrial respiration. Raising NAD+ levels is well-documented; translating that increase into consistent human metabolic benefit is not.
Why these three are complementary, not redundant
A useful way to keep the three distinct: SS-31 works on the mitochondrial machinery itself (structural/membrane); MOTS-c functions as a metabolic-stress signal that influences how cells respond to energetic demand; NAD+ is the coenzyme currency cells need to run the reactions that convert nutrients into usable energy in the first place. Rankings shift depending on the research question — MOTS-c has the strongest mechanistic story for insulin sensitivity specifically, NAD+ has the most human trial data (with mixed results), and SS-31 has the most mitochondrial-performance-specific mechanism along with the most clinical development of the three.
Open questions for researchers
Several questions remain genuinely open. Does SS-31’s mitochondrial membrane effect translate into measurable insulin-sensitivity change in non-Barth-syndrome populations, or does the mechanism stay indirect? Why do NAD-precursor trials produce such inconsistent metabolic results across similar-seeming study populations — is it a dosing, duration, or baseline-NAD+ question? And as FDA’s 503A rulemaking process for MOTS-c and the other PCAC-reviewed peptides continues, how will that formal decision — expected to follow the committee’s non-binding recommendation — affect the research-compound supply landscape for mitochondrial-signaling peptides specifically?
All compounds referenced in this article are available for research use only. This article is provided for informational and educational purposes. No therapeutic claims are made or implied.